European Journal of Clinical Pharmacology

, Volume 28, Issue 4, pp 405–410 | Cite as

Pharmacokinetics of verapamil in patients with renal failure

  • J. Mooy
  • M. Schols
  • M. v. Baak
  • M. v. Hooff
  • A. Muytjens
  • K. H. Rahn
Originals

Summary

The pharmacokinetics of verapamil was studied in patients with end-stage chronic renal failure and in normal subjects after i.v. injection of 3 mg and a single oral dose of 80 mg. Plasma levels of verapamil and its active metabolite norverapamil were measured by HPLC. After i.v. injection, the terminal phase half-life and total plasma clearance of verapamil in both groups were similar. Haemodialysis did not change the time course of plasma verapamil levels after i.v. administration. After a single oral dose, the plasma levels of verapamil and norverapamil in both groups of subjects were similar. Subsequently, normal volunteers and patients with renal failure were treated for 5 days with oral verapamil 80 mg t.d.s. There was no difference between the 2 groups of subjects in the trough and peak levels of verapamil or of norverapamil. Intravenous and oral administration of the calcium channel blocking agent had similar effects on blood pressure, heart rate and the PR-interval in the electrocardiogram in both groups. The study demonstrated that the disposition of verapamil was similar in normal subjects and in patients with renal failure.

Key words

verapamil renal failure norverapamil pharmacokinetics haemodialysis ECG blood pressure heart rate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dixon WJ, Brown MB (1981) Biomedical computer programs P-series (BMDP-81). University of California Press, Berkeley, pp 290–304Google Scholar
  2. Dominic JA, Bourne DWA, Tan TG, Kirsten EB, McAllister RG Jr (1981) The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J Cardiovasc Pharmacol 3: 25–38Google Scholar
  3. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ (1979) The metabolism of DL-(14C)-verapamil in man. Drug Metab Dispos 7: 145–148Google Scholar
  4. Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1981) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D, L-verapamil using stable isotopelabelled verapamil. Eur J Clin Pharmacol 19: 133–137Google Scholar
  5. Harapat SR, Kates RE (1979) Rapid high-pressure liquid chromatography analysis of verapamil in blood and plasma. J Chromatogr 170: 385–390Google Scholar
  6. Harapat SR, Kates RE (1980) High-performance liquid chromatographic analysis of verapamil II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatogr 181: 484–489Google Scholar
  7. Kates RE (1983) Calcium antagonists: pharmacokinetic properties. Drug 25: 113–124Google Scholar
  8. Keefe DL, Yee YG, Kates RE (1981) Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 29: 21–26Google Scholar
  9. Koike Y, Shimamura K, Shudo I, Saito H (1979) Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol 24: 37–47Google Scholar
  10. Lienert GA (1973) Verteilungsfreie Methoden in der Biostatistik. Anton Hein, Meisenheim, p 473Google Scholar
  11. McAllister RG, Kirsten EB (1982) The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31: 418–426Google Scholar
  12. Neugebauer G (1978) Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetized dog. Cardiovasc Res 12: 247–254Google Scholar
  13. Pozet N, Brazier JL, Hadj Aissa A, Khenfer D, Faucon G, Apoli E, Traeger J (1983) Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol 24: 635–638Google Scholar
  14. Schols M, Mooy J, v. Hooff M, v. Baak MA, Rahn KH (1983) Studies on the disposition of verapamil in patients with renal failure. Naunyn-Schmiedebergs Arch Pharmacol 322 [Suppl]: R 130Google Scholar
  15. Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10: 605–612Google Scholar
  16. Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC (1982) Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J 104: 198–203Google Scholar
  17. Tartaglione TA, Pieper JA, Lopez LA, Mehta J (1983) Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. Res Commun Chem Pathol Pharmacol 40: 15–27Google Scholar
  18. Zerbe GO (1979a) Randomization analysis of the completely randomized design extended to growth and response curves. J Am Stat Assoc 74: 215–221Google Scholar
  19. Zerbe GO (1979b) Randomization analysis of randomized block design extended to growth and response curves. Commun Stat Theor Methodol A8 [2]: 191–205Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • J. Mooy
    • 1
  • M. Schols
    • 2
  • M. v. Baak
    • 2
  • M. v. Hooff
    • 1
  • A. Muytjens
    • 3
  • K. H. Rahn
    • 1
  1. 1.Department of Internal Medicine, Division of NephrologyHypertension and Clinical PharmacologyMaastrichtThe Netherlands
  2. 2.Department of PharmacologyUniversity of LimburgMaastrichtThe Netherlands
  3. 3.Department of StatisticsUniversity of LimburgMaastrichtThe Netherlands

Personalised recommendations